Is biopharma’s first $1.5M therapy now in Phase III? – Endpoints News
Endpoints News |
Is biopharma's first $1.5M therapy now in Phase III?
Endpoints News Keying off of Spark Therapeutics' rollout of Luxturna as the first approved gene therapy in the US, the analysts at Leerink have been crunching the numbers on what the first hemophilia gene therapies could fetch. And by raising their estimate to $1.5 … |
